Full Year 2024 Biomerieux SA Earnings Call Transcript
Key Points
- BioMerieux SA (BMXMF) reported a strong sales growth of 10.3% in 2024, surpassing their target of 7% compounded growth rate over five years.
- The company achieved a 20% improvement in profitability at constant exchange rates, exceeding their revised target of 12% to 17%.
- Free cash flow generation was robust at EUR330 million, nearly tripling from 2023.
- The company successfully reduced greenhouse gas emissions by 13% in absolute terms compared to 2019.
- BioMerieux SA (BMXMF) maintained its market leadership in syndromic testing, with significant new unit installations in 2024.
- VIDAS sales declined by 5% in 2024, with a notable 20% decline in PCT sales.
- The company faced a EUR49 million impairment related to its China immunoassay entity, Hybiome, due to strong price pressure in the market.
- There was a slight increase in inventory levels, which the company is working to manage more effectively.
- The lost day incident rate, a safety indicator, did not meet the company's expectations, indicating room for improvement.
- BioMerieux SA (BMXMF) anticipates a foreign exchange impact of approximately EUR30 million on CEBIT in 2025.
Good day, and welcome to the bioMérieux's fourth-quarter sales and full-year 2024 results conference call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Aymeric Fichet. Please go ahead.
Thanks. So good afternoon, everyone, and thank you for joining us to review the bioMérieux 2024 financial performance. I'm on line with Pierre Boulud, CEO; together with Guillaume Bouhours, CFO.
Before handing the call over to Pierre and Guillaume, please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve these objectives. I also remind you that today's call is being recorded and that a replay will be available on our website.
I will now hand the call over to Pierre and then we will open the call to discussion and questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
